Aspire Biopharma Holdings, Inc. · NASDAQ:ASBP
Aspire Biopharma — Investor Presentation (June 2025)
20 slides from Aspire Biopharma's investor presentation, June 2025
Slide 1: Investor Presentation June 2025
June 2025 Investor Presentation Nasdaq: ASBP
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements made in this presentation are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such
Slide 3: Overview
Overview Patent-pending drug delivery technology for rapid sublingual absorption and entry into the bloodstream of supplements and other substances ▪ Science Team-Disruptive Technology ▪ Market Opportunity: >$100 billion ▪ Contract Manufacturing ▪ Lead Rx Product: Sublingual Aspirin ▪ Lead Consumer
Slide 4: Overview – The Technology
Overview – The Technology Aspire Biopharma has developed Technology delivers a fast New mechanism of delivery disruptive technologies for acting drug formulations using (absorption pathway) allows delivering drugs and other rapid sublingual absorption products sublingually(1). our patent-pending met
Slide 5: Technology Overview
Technology Overview Fast Acting Powder-form medication developed using our patent-pending technology enters the bloodstream in a fraction of the time as compared to oral tablets and capsules Water Soluble Dissolves easily under the tongue Dosage Management Drugs do not first pass through the liver a
Slide 6: Delivery Method
Delivery Method Mouth to Blood Stream Pathways Nature Provides the mouth with Direct Access to Blood Stream Dorsalis Lingual Artery Lingual Vein Aspire’s sublingual delivery system avoids the Veins of Dorsum of Tongue side effect drugs delivered in pills or tables orally ▪ Avoid damage to GI tract ▪
Slide 7: Aspire Product Pipeline & Planned 2025 Milestones
Aspire Product Pipeline & Planned 2025 Milestones Aspirin Products Non-Aspirin Prescription Drug Products ▪ Testosterone formulation for sublingually administration. High Dose ▪ Phase 1 clinical test planned for 3Q 2025. ✓ Commenced clinical trial to evaluate the pharmacodynamic ▪ Sublingual semaglu
Slide 8: Market Opportunity
Market Opportunity Aspire believes its disruptive technology can be applied to a number of approved drugs and supplements Global Analgesics Market Valued at $47.32B in 2023 and projected to reach $75.73B by 2032, growing at a compound annual growth rate (CAGR) of 5.39% over the forecast period 2024-
Slide 9: Manufacturing Strategy
Manufacturing Strategy A contract manufacturing strategy is being pursued with the potential for multiple supplier relationships to reduce risk and capex investments Glatt Air Techniques ▪ Technical Manufacturing Development Partner ▪ Pharmaceutical Development Agreement signed June 2022 ▪ Produced
Slide 10: Sublingual Aspirin Product: Overview
Sublingual Aspirin Product: Overview ▪ Addresses cardiology emergencies and pain management Absorption Level Illustration* ▪ Granular or powder formulation of a soluble, fast-acting aspirin ▪ Developed using patent-pending formulation, and "trade secret” process Benefits of “rapid absorption” aspiri
Slide 11: Sublingual Aspirin Product: Background
Sublingual Aspirin Product: Background Oral aspirin (ASA) with it’s anti-inflammatory properties has been used world-wide for over 100 years Aspirin is one of the most-studied and understood drugs, and universally approved for use. In the past Aspirin-induced GI bleeding has limited the long-term or
Slide 12: Sublingual Aspirin Product: Proof of Concept
Sublingual Aspirin Product: Proof of Concept The Proof-of-Concept study verifies and validates that our formula enters the bloodstream with a therapeutic cardiac dose of aspirin in less than one minute There is no oral form of aspirin on the market today that ▪ can be absorbed into the bloodstream i
Slide 13: Sublingual Aspirin Product: Clinical Trials
Sublingual Aspirin Product: Clinical Trials Strategy Aspire uses existing, approved generic-drug dosages. Generic drugs do not need to repeat the clinical trials related to active ingredients but must demonstrate sublingual route of administration • effectiveness • amount of drug that gets to the bl
Slide 14: Sublingual Aspirin Product Commercialization and Go-to-Market Strategy
Sublingual Aspirin Product Commercialization and Go-to-Market Strategy Launch product initially in the Rx market, followed by an OTC version Partner with an experienced end-to-end marketing and distribution firms Significant potential licensing opportunity with leading drug manufacturers (cited in t
Slide 15: Sublingual Aspirin Product: Analgesics Market Opportunity
Sublingual Aspirin Product: Analgesics Market Opportunity Non-opioid analgesic and opioid markets combined currently estimated at $80+B and projected to grow to nearly $100B in five years 2022 2023 2024 2025 2026 2027 Market Data ($-Bil) Opioids $32.5 $33.6 $34.6 $35.7 $36.8 $37.9 Analgesics $48.0 $
Slide 16: BUZZ BOMB New Sublingual Pre-Workout Supplement
BUZZ BOMB New Sublingual Pre-Workout Supplement Single serving pre-workout caffeine supplement utilizing Aspire's patent-pending and proprietary sublingual delivery technology • Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the P
Slide 17: Pre-Workout Supplement Market
Pre-Workout Supplement Market • Global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030 ❖ Rising fitness culture and gym memberships ❖ Consumer focus on performance and recovery ❖ Expanding demographics (women, Gen Z, casua
Slide 18: BUZZ BOMB Disruptive Characteristics
BUZZ BOMB Disruptive Characteristics • Speed - works nearly immediately vs. 20-30 minutes • Convenience - easy to use small packets vs. mix beverages • Energy management - use as needed, when needed to manage energy • Single Safe Ingredients - well known benefits and use of caffeine • Low manufactur
Slide 19: Aspire’s Investment Considerations
Aspire’s Investment Considerations Opportunity: ▪ Large Addressable Market: $80B combined analgesics and opioid market ▪ Prescription: Expect to file in late 2025 to meet FDA 505 (b)(2) Fast Track drug approval process ▪ OTC: OTC version for FDA compliance in accordance with the existing monograph ▪
Slide 20: Thank You.
Aspire BioPharma Holdings, Inc. 23150 Fashion Drive, Suite 232 Thank You. Estero, FL 33928 www.aspirebiolabs.com info@aspire-biopharma.com Investor Relations investors@aspire-biopharma.com Nasdaq: ASBP 20
Aspire Biopharma Holdings — Investor Presentation (June 2025) on 6ix